| Name | Title | Contact Details |
|---|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Karuna Pharmaceuticals is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.
MAP Pharmaceuticals is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)